罗氏制药助力消化道肿瘤药物创新,面向中国征集合作伙伴,将提供资金、药物及研发支持

2020-07-07 MedSci原创 MedSci原创

该合作专项计划将用于支持中国创新型企业合作研发针对消化道肿瘤的新疗法。

(2020年7月6日,上海)今天,罗氏制药中国宣布,为满足中国广大消化道肿瘤患者的未尽之需,推动中国消化道肿瘤药物创新,罗氏将从即日正式启动专门面向中国的“消化道肿瘤免疫联合治疗合作专项计划”(简称“合作专项计划”),该合作专项计划将用于支持中国创新型企业合作研发针对消化道肿瘤的新疗法,并提供包括资金、免费研究药物以及研发策略等在内的多种支持。

中国消化道肿瘤的发病率占总体肿瘤发病率的40%左右,明显高于世界平均水平,很多消化道肿瘤在中国的发病人数都占全球总发病人数的50%以上,例如肝癌、食管癌、胃癌等。此外,中国每年因消化道肿瘤死亡人数占年肿瘤致死人数的50%,大多数消化道肿瘤患者的整体5年生存率更是低于20%,如中国胃癌的5年生存率为20%,肝癌的5年生存率为12.5%,食管癌的5年生存率为15%,而胰腺癌的5年生存率仅为7.2%。

“罗氏在消化道肿瘤领域一直持续投入,并积极将各种消化道肿瘤创新药物带入中国。面对广大中国消化肿瘤患者的未尽之需,我们期待着通过本次合作专项计划,能够支持中国在消化肿瘤治疗领域实现更多、更快、更好的突破。”罗氏制药全球消化肿瘤负责人Peter Ahnesorg表示。

“罗氏消化道肿瘤免疫联合治疗合作专项计划” 将在5年内面向所有中国创新医药企业开放申请,具体支持方式包括但不限于向中国药企提供罗氏肿瘤免疫产品泰圣奇®(阿替利珠单抗)和靶向药物安维汀®(贝伐珠单抗)在内的研究药物,通过与国内创新药企的在研药物开展联合研究,探索创新的消化道肿瘤治疗方法。该计划还将在双方协商一致的前提下提供研发资金,在合作过程中罗氏制药还会对国内创新药企提供科学及研发支持,以帮助其优化策略并加速研发进程。

罗氏制药中国总裁周虹表示:“随着中国将生物医药列为战略产业,以及中国政府对医药创新的大力扶持,中国正在成为全球医药创新的热土,中国研发新药数量的全球贡献率已达7.8%。罗氏制药长期扎根中国,并积极探索与各方合作,本次专项计划的启动,也将开启罗氏与中国科研机构、本土创新企业开展广泛合作的序幕。”

“罗氏消化道肿瘤免疫联合治疗合作专项计划”

合作对象

面向所有中国创新医药企业开放申请

合作范围/要求:

1. 创新分子、创新靶点或创新技术

2. 作用机制明确

3. 产权/专利清晰

4. 药物联合的科学依据合理

5. 产品尚未上市

合作方式:

1. 中国创新医药企业提出合作需求并提供必要前期数据

2. 罗氏制药团队评估可行后双方签订合作协议

3. 研发由申请方负责实施,亦可经双方协商采取最佳的合作方式开发

联系方式:

china.collaboration@roche.com

# # #

关于罗氏在消化道肿瘤领域

作为个体化医疗的引领者,罗氏一直在消化道肿瘤领域进行长期投资研发创新药物,并积极将创新药物带入中国。目前罗氏针对胃癌、结直肠癌的希罗达®(卡培他滨)、安维汀®(贝伐珠单抗)、赫赛汀®(曲妥珠单抗)等药物都已经惠及了数以万计的中国消化道肿瘤患者,肿瘤免疫产品泰圣奇®(阿替利珠单抗)联合安维汀®(贝伐珠单抗)治疗一线不可切除晚期肝细胞癌也有望于近期在中国获批。此外,罗氏还在结直肠癌、食管癌、胆管癌等消化肿瘤领域进行大规模创新药物研发。

关于泰圣奇® 

阿替利珠单抗是一种设计用于直接与肿瘤细胞和肿瘤浸润免疫细胞上表达的PD-L1配体蛋白结合的单克隆抗体,可阻断其与PD-1和B7.1受体的相互作用。通过阻断PD-L1通路,泰圣奇® 可以有效激活T细胞。作为一种创新癌症免疫治疗方法,泰圣奇®有望作为联合治疗的基础用药,与其他免疫疗法、靶向药物和各种化疗药联合用于治疗多种癌症。

目前,泰圣奇®已在美国、欧盟和世界各国获得批准,作为单药治疗或联合靶向疗法和/或化疗用于治疗非小细胞肺癌和小细胞肺癌、特定类型转移性尿路上皮癌和PD-L1高表达的转移性三阴性乳腺癌等多种类型的癌症。2020年2月13日,泰圣奇®联合化疗用于一线治疗广泛期的小细胞肺癌在中国获批。2月28日,中国国家药品监督管理局正式授予泰圣奇®联合安维汀®用于一线治疗晚期不可切除的肝细胞癌的优先审评资格

关于安维汀®

安维汀®是一种通过静脉输注的处方药,是一种生物学抗体,能够与VEGF蛋白特异性结合,而VEGF在肿瘤的整个生命周期中在血管新生和血管维护方面具有重要作用,这一过程被称为血管生成。安维汀®通过直接与VEGF蛋白结合以防止与血管细胞上的受体相互作用来干扰肿瘤的血液供应。肿瘤的血液供应被认为是肿瘤在体内生长和扩散(转移)能力的关键。

关于泰圣奇®联合安维汀®

泰圣奇®联合安维汀®具有扎实的科学依据。二者联合具有提高人体自身免疫系统对抗多种肿瘤的潜力。安维汀的抗血管生成作用可以进一步加强泰圣奇的肿瘤免疫疗效,降低VEFG相关免疫抑制,提高T细胞对肿瘤抗原反应。

关于罗氏的癌症免疫疗法研究

50多年来,罗氏一直致力于开发创新药物,重新定义癌症的治疗。今天,我们投入比以往更多的资源,致力于研发创新的治疗方案,帮助激活患者自身免疫系统以抗击癌症。

通过设计肿瘤免疫周期框架,并在框架下开展肿瘤免疫分析领域的开拓性研究,罗氏正在加速推进并扩大应用泰圣奇®给更广大的癌症患者所带来的临床获益。我们的癌症免疫疗法研究采用了综合方案来实现重建免疫力抗击肿瘤的目标,以改善患者预后。

关于罗氏集团

罗氏是全球制药和诊断领域的领导者,致力于通过推动科学进步,改善人类生活。结合了制药和诊断两大业务的独特优势使罗氏集团成为个体化医疗的领导者,通过个体化医疗为每一位患者提供最具针对性的治疗方案。

罗氏是全球最大的生物技术公司,并且在肿瘤、免疫、感染性疾病、眼科和中枢神经系统疾病领域拥有一流的差异化药物。罗氏在全球体外诊断和基于组织的肿瘤诊断领域享有领导地位,同时也是糖尿病管理领域的先驱者。

自1896年成立以来,罗氏始终致力于不断探索更好的疾病预防、诊断和治疗方案,持续为社会做出贡献。同时,公司通过与有关的利益相关方开展密切合作,提升患者对于创新药物的可及性。在世界卫生组织基本药物目录中,有30多个由罗氏研发的药品,包括用以挽救生命的抗生素、抗疟药和抗肿瘤药物。而且,罗氏连续十一年位列道琼斯可持续发展指数(DJSI)制药行业中最具可持续性发展的公司之一。

罗氏集团总部位于瑞士巴塞尔,业务遍及全球100多个国家,2019年罗氏全球员工超过98,000名。2019年罗氏研发投资117亿瑞士法郎,总销售额达 615 亿瑞士法郎。美国基因泰克公司(Genentech)是罗氏集团的全资子公司,罗氏也是日本中外制药株式会社(Chugai)的控股方。更多相关信息,请访问www.roche.com

关于罗氏中国

罗氏与中国的渊源可以追溯到上世纪20、30年代,罗氏在上海开始了其药品销售。1994年,上海罗氏制药有限公司在上海张江正式成立,成为首家进驻张江高科技园区的跨国企业。2004年,成立了罗氏研发(中国)有限公司,成为在上海首家独资设立研发中心的跨国药企;2007年,罗氏全球药品开发上海中心成立,推动并加速了罗氏创新药品在中国的临床开发及注册。2009年,该中心加入罗氏全球药品开发中心并成为其在全球的五个药品开发中心之一。

在大型跨国药企中,罗氏率先建成了包括研究、开发、生产、营销等环节在内的完整医药价值产业链,为中国患者提供抗肿瘤、抗感染及抗病毒、移植、风湿免疫等多个关键治疗领域的突破性药品。目前,罗氏在华拥有22款产品,覆盖8个治疗领域。

立足中国,造福中国与世界:罗氏持续加强对中国的投入,尤其是研发创新的投入。2015年,罗氏投资8.63亿建设全新的罗氏上海创新中心,并于2019年正式落成。全新的创新中心聚焦于研究与早期开发免疫、炎症及抗感染疾病领域的创新型药品。未来,它将有效促进罗氏与本土科研机构的合作,持续不断地为中国和全球患者开发优异创新的药品。此外,创新中心配备了世界一流的研究设施,吸引海内外顶尖创新医药人才不断涌入。秉承“先患者之需而行”的承诺,上海是罗氏继旧金山和巴塞尔之后的第三大全球战略中心。

随着改革开放的不断深化,中国政府推出了一系列医疗改革的新举措,尤其是在加速新药注册审批流程、更新国家医保目录等方面。目前,罗氏共有七款靶向药物——赫赛汀®、安维汀®、特罗凯®、佐博伏®、安圣莎®、帕捷特®、美罗华®及一款生物制剂——雅美罗®被列入国家医保目录,惠及中国患者。此举不但极大降低了癌症患者的经济负担,也促进了中国肿瘤治疗领域的规范化发展。

罗氏将积极与政府、医疗机构以及非政府组织等社会各界多方携手,共同探索创新的合作模式,通过一系列有影响力和可持续的举措惠及更多的中国患者。

更多关于罗氏制药中国的信息,请登陆罗氏中国网站 www.roche.com.cn

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=881685, encodeId=fe828816855b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 01 08:21:42 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285881, encodeId=cb4c128588182, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300406, encodeId=a9d61300406b8, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394161, encodeId=e11c139416138, content=<a href='/topic/show?id=9cf1e961338' target=_blank style='color:#2F92EE;'>#罗氏制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79613, encryptionId=9cf1e961338, topicName=罗氏制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446805, encodeId=f80f144680586, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464664, encodeId=e26914646643e, content=<a href='/topic/show?id=32e765e6591' target=_blank style='color:#2F92EE;'>#消化道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65765, encryptionId=32e765e6591, topicName=消化道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b6e6676048, createdName=changhe715, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537745, encodeId=8534153e74525, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=)]
    2020-09-01 14818eb4m67暂无昵称

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=881685, encodeId=fe828816855b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 01 08:21:42 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285881, encodeId=cb4c128588182, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300406, encodeId=a9d61300406b8, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394161, encodeId=e11c139416138, content=<a href='/topic/show?id=9cf1e961338' target=_blank style='color:#2F92EE;'>#罗氏制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79613, encryptionId=9cf1e961338, topicName=罗氏制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446805, encodeId=f80f144680586, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464664, encodeId=e26914646643e, content=<a href='/topic/show?id=32e765e6591' target=_blank style='color:#2F92EE;'>#消化道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65765, encryptionId=32e765e6591, topicName=消化道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b6e6676048, createdName=changhe715, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537745, encodeId=8534153e74525, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=881685, encodeId=fe828816855b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 01 08:21:42 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285881, encodeId=cb4c128588182, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300406, encodeId=a9d61300406b8, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394161, encodeId=e11c139416138, content=<a href='/topic/show?id=9cf1e961338' target=_blank style='color:#2F92EE;'>#罗氏制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79613, encryptionId=9cf1e961338, topicName=罗氏制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446805, encodeId=f80f144680586, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464664, encodeId=e26914646643e, content=<a href='/topic/show?id=32e765e6591' target=_blank style='color:#2F92EE;'>#消化道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65765, encryptionId=32e765e6591, topicName=消化道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b6e6676048, createdName=changhe715, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537745, encodeId=8534153e74525, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=)]
    2020-07-09 lqvr
  4. [GetPortalCommentsPageByObjectIdResponse(id=881685, encodeId=fe828816855b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 01 08:21:42 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285881, encodeId=cb4c128588182, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300406, encodeId=a9d61300406b8, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394161, encodeId=e11c139416138, content=<a href='/topic/show?id=9cf1e961338' target=_blank style='color:#2F92EE;'>#罗氏制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79613, encryptionId=9cf1e961338, topicName=罗氏制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446805, encodeId=f80f144680586, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464664, encodeId=e26914646643e, content=<a href='/topic/show?id=32e765e6591' target=_blank style='color:#2F92EE;'>#消化道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65765, encryptionId=32e765e6591, topicName=消化道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b6e6676048, createdName=changhe715, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537745, encodeId=8534153e74525, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=881685, encodeId=fe828816855b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 01 08:21:42 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285881, encodeId=cb4c128588182, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300406, encodeId=a9d61300406b8, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394161, encodeId=e11c139416138, content=<a href='/topic/show?id=9cf1e961338' target=_blank style='color:#2F92EE;'>#罗氏制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79613, encryptionId=9cf1e961338, topicName=罗氏制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446805, encodeId=f80f144680586, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464664, encodeId=e26914646643e, content=<a href='/topic/show?id=32e765e6591' target=_blank style='color:#2F92EE;'>#消化道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65765, encryptionId=32e765e6591, topicName=消化道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b6e6676048, createdName=changhe715, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537745, encodeId=8534153e74525, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=881685, encodeId=fe828816855b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 01 08:21:42 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285881, encodeId=cb4c128588182, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300406, encodeId=a9d61300406b8, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394161, encodeId=e11c139416138, content=<a href='/topic/show?id=9cf1e961338' target=_blank style='color:#2F92EE;'>#罗氏制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79613, encryptionId=9cf1e961338, topicName=罗氏制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446805, encodeId=f80f144680586, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464664, encodeId=e26914646643e, content=<a href='/topic/show?id=32e765e6591' target=_blank style='color:#2F92EE;'>#消化道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65765, encryptionId=32e765e6591, topicName=消化道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b6e6676048, createdName=changhe715, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537745, encodeId=8534153e74525, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=881685, encodeId=fe828816855b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 01 08:21:42 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285881, encodeId=cb4c128588182, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300406, encodeId=a9d61300406b8, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394161, encodeId=e11c139416138, content=<a href='/topic/show?id=9cf1e961338' target=_blank style='color:#2F92EE;'>#罗氏制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79613, encryptionId=9cf1e961338, topicName=罗氏制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446805, encodeId=f80f144680586, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464664, encodeId=e26914646643e, content=<a href='/topic/show?id=32e765e6591' target=_blank style='color:#2F92EE;'>#消化道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65765, encryptionId=32e765e6591, topicName=消化道)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b6e6676048, createdName=changhe715, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537745, encodeId=8534153e74525, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Thu Jul 09 05:28:37 CST 2020, time=2020-07-09, status=1, ipAttribution=)]

相关资讯

CSCO会议期间召开“HER TALKS”卫星会 乳此美丽,愈见未来

2017年CSCO学术年会在风光旖旎的厦门如期而至。2017年是值得纪念和庆贺的一年,今年是CSCO 成立20周年,在这一年当中,肿瘤学届也发生了很多大事。2017年7月19日人力资源和社会保障部宣布:将注射用曲妥珠单抗(赫赛汀?)等36种药品纳入《国家基本医疗保险、工伤保险和生育保险药品目录(2017年版)》乙类范围,这意味着全国众多的HER2阳性乳腺癌患者有机会接受抗HER2靶向治疗。为了更好